Overview

Tadalafil in Subjects With Mild to Moderate Hypertension

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
Purpose: The primary objective of this study is to evaluate the efficacy and safety of tadalafil when administered once daily at doses of 5 and 20 mg to adult subjects for 8 weeks with mild to moderate hypertension.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
ICOS Corporation
Treatments:
Tadalafil